Role of 18F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications
Cancers · 16.05.2024 · 16 (10) · 1905
DOI: 10.3390/cancers16101905 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.05.2024. Verfasst von Carmelo Caldarella und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Unit, Department of Radiology and Oncologic Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This article provides an overview of the use of 18F-FDG PET/CT in various clinical scenarios of head–neck squamous cell carcinoma, ranging from initial staging to treatment-response assessment, and post-therapy follow-up, with a focus on the current evidence, debated issues, and innovative applications. Methodological aspects and the most frequent pitfalls in head–neck imaging interpretation are described. In the initial work-up, 18F-FDG PET/CT is recommended in patients with metastatic cervical lymphadenectomy and occult primary tumor; moreover, it is a well-established imaging tool for detecting cervical nodal involvement, distant metastases, and synchronous primary tumors. Various 18F-FDG pre-treatment parameters show prognostic value in terms of disease progression and overall survival. In this scenario, an emerging role is played by radiomics and machine learning. For radiation-treatment planning, 18F-FDG PET/CT provides an accurate delineation of target volumes and treatment adaptation. Due to its high negative predictive value, 18F-FDG PET/CT, performed at least 12 weeks after the completion of chemoradiotherapy, can prevent unnecessary neck dissections. In addition to radiomics and machine learning, emerging applications include PET/MRI, which combines the high soft-tissue contrast of MRI with the metabolic information of PET, and the use of PET radiopharmaceuticals other than 18F-FDG, which can answer specific clinical needs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nuclear Medicine Unit, Department of Radiology and Oncologic Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
- Radiation Oncology Unit, Department of Radiology and Oncologic Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
- Radiation Oncology Unit, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy.
- Otorhinolaryngology Operative Unit, Azienda Ospedaliero Universitaria Sassari, 07100 Sassari, Italy.
- Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
- Otorhinolaryngology Unit, Department of Neurosciences, Sensory Organs and Thorax, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
ORCID-Profile: Carmelo Caldarella, Francesco Bussu, Vittoria Rufini, Lucia Leccisotti
Zitieren
APA
Caldarella, C., De Risi, M., Massaccesi, M., Miccichè, F., Bussu, F., Galli, J., Rufini, V., & Leccisotti, L. (2024). Role of 18F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications. Cancers, 16(10), 1905. https://doi.org/10.3390/cancers16101905
Vancouver
Caldarella C, De Risi M, Massaccesi M, Miccichè F, Bussu F, Galli J, et al. Role of 18F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications. Cancers. 2024;16(10):1905. doi:10.3390/cancers16101905
BibTeX
@article{Caldarella2024,
author = {Caldarella, Carmelo and De Risi, Marina and Massaccesi, Mariangela and Miccichè, Francesco and Bussu, Francesco and Galli, Jacopo and Rufini, Vittoria and Leccisotti, Lucia},
title = {Role of 18F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications},
journal = {Cancers},
year = {2024},
volume = {16},
number = {10},
pages = {1905},
doi = {10.3390/cancers16101905}
}
EUVIMED